Strata Critical Medical, Inc. (SRTAW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Strata Critical Medical, Inc. (SRTAW) operates by delivering time-critical logistics and specialized medical services specifically designed for the United States healthcare sector. Although the specific sector and industry classifications are not disclosed in the provided data, the company functions within a niche that supports essential medical operations including organ transportation and the movement of transplant teams. The entity employs a workforce of 327 individuals to manage its dual-segment structure comprising Logistics and Clinical divisions. Given that the market capitalization, price-to-sales ratio, and other standard valuation multiples are currently unavailable, the scale of the operation is primarily defined by its reported annual revenue of $197.14 million, which indicates a significant operational footprint despite the absence of a listed market cap figure to quantify its public valuation.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $197.14 million, yet this generated a net income of -$20,066,000 and an EBITDA of -$5,709,000, revealing a substantial gap between top-line sales and bottom-line profitability that suggests high operational costs or significant one-time expenses impacting the current fiscal period. The free cash flow stands at -$26,982,624, indicating that the company is currently burning cash rather than generating liquidity from its operations, which limits immediate financial flexibility for capital expenditures without external financing. While the profit margin figure is listed as 21.0%, this appears inconsistent with the negative net income and should be viewed alongside the gross margin of 20.9% and operating margin of -5.3%, where the negative operating margin highlights that operating expenses exceed operating income before interest and taxes. In terms of liquidity management, the company holds $61.23 million in cash against total debt of $3.31 million, resulting in a debt-to-equity ratio of 1.19 which suggests a leveraged balance sheet despite the ample cash reserves. The current ratio is an exceptionally high 6.38, indicating robust short-term liquidity where current assets significantly outweigh current liabilities, providing a strong buffer against immediate financial obligations. Additionally, the return on equity is -8.0% and the return on assets is -2.7%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the business, reflecting the ongoing losses characteristic of the company's current financial state.

मूल्यांकन आकलन

Since the trailing P/E ratio and forward P/E ratio are both listed as unavailable (N/A), no direct comparison of expected earnings trajectories can be made through these traditional multiples at this time. The price-to-book ratio is recorded as 0.00, which typically indicates that the company's market capitalization is negligible or that the book value exceeds the market price, suggesting the market does not assign a premium to the company's assets relative to its equity. Similarly, the price-to-sales ratio and EV/EBITDA multiples are unavailable, meaning alternative valuation metrics cannot currently be used to assess the company's relative standing against peers. Regarding price action, the 52-week high and low are both recorded at $0.01, meaning the current trading price is effectively at the lower bound of its recent trading range with no discernible premium or discount relative to the high. The beta value is 2.11, which signifies that the stock price is highly volatile and expected to fluctuate with significantly greater magnitude than the broader market index, implying heightened risk for traders sensitive to market movements.

Growth & Income

The revenue growth year-over-year is reported at 83.5%, while the earnings growth year-over-year is unavailable (N/A); this disparity implies that while the top line is expanding rapidly, the profitability required to convert that revenue into earnings has not yet materialized in a measurable growth rate. As the company does not pay dividends, evidenced by the unavailable dividend yield and payout ratio, it follows a capital allocation strategy of reinvesting all available earnings back into the business to fund growth initiatives rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by aggressive top-line expansion coupled with a lack of current income generation, positioning the entity as a pure growth play that relies on future operational efficiencies to eventually achieve profitability.